---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-206396"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:24:25.346587+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# OnKure Q1 loss $15.2M; cash $192M; nominates two new PI3Kα inhibitors; halting OKI-219

## Summary
- Net loss of $15.2M ($1.11 per share) for Q1 2026 vs $15.9M ($1.19 per share) in Q1 2025.
- Cash and cash equivalents $192.1M as of March 31, 2026, including $150M private placement closed on March 31, expected to fund operations into 2029.
- Announced nomination of OKI-355 for vascular anomalies and OKI-345 for breast cancer; IND submissions planned for first half 2027.
- Company will not independently pursue further clinical development of OKI-219; data from PIKture-01 study to be reported by end of 2026.
- R&D expenses $11.7M (down from $13.0M), G&A $3.9M (down from $4.0M).

## SEC filing metadata
- accession: 0001193125-26-206396
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000119312526206396/0001193125-26-206396-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000119312526206396/okur-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-206396
- JSON: https://secwatch.observer/filing/0001193125-26-206396.json
- Plain text: https://secwatch.observer/filing/0001193125-26-206396.txt

## Source-grounded claims
- claim_id: 76868286ada40c91eb7230c6b3249af0aceffaaa
  claim: OnKure Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.
  evidence_excerpt: OnKure Therapeutics, Inc. issued a press release reporting financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000119312526206396/0001193125-26-206396-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.